vTv Therapeutics (VTVT) Net Equity Issued and Repurchased (2018 - 2022)

vTv Therapeutics (VTVT) has 5 years of Net Equity Issued and Repurchased data on file, last reported at -$5.0 million in Q4 2022.

• For the quarter ending Q4 2022, Net Equity Issued and Repurchased fell 880.19% year-over-year to -$5.0 million; the trailing twelve-month figure through Dec 2024 stood at -$5.0 million (changed 0.0% YoY), and the FY2024 full-year result was $2.5 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased eased to -$5.0 million in Q4 2022, from $646000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $17.0 million in Q3 2021 to a low of -$5.0 million in Q4 2022.
• A 5-year average of $5.2 million and a median of $5.4 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 16876.74% in 2020 and plunged 880.19% in 2022, its largest moves.
• Tracing VTVT's Net Equity Issued and Repurchased over 5 years: stood at $6.5 million in 2018, then tumbled by 99.34% to $43000.0 in 2019, then jumped by 10818.6% to $4.7 million in 2020, then tumbled by 86.24% to $646000.0 in 2021, then sank by 880.19% to -$5.0 million in 2022.
• Business Quant data shows VTVT's Net Equity Issued and Repurchased at -$5.0 million in Q4 2022, $646000.0 in Q4 2021, and $17.0 million in Q3 2021.